Aug. 4, 2011
Cumberland Pharmaceuticals Inc.
(Nasdaq: CPIX) today announced that it has executed a new senior credit agreement with Bank of America. Pursuant to the new agreement, the Company has increased its revolving line of credit to
, which is expandable to
. In addition, the maturity date for the new facility has been extended to
The new bank agreement replaces
's previous financing arrangement with Bank of America, which was negotiated prior to the Company's initial public offering in 2009 and included a term loan and credit facility. Cumberland recently completed principal payments on the term loan.
"We have enjoyed a long-standing relationship with Bank of America and appreciate its confidence in our Company as reflected by this expanded line of credit," said
, Chief Executive Officer of Cumberland Pharmaceuticals.
About Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Inc. is a
-based specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company's primary target markets include hospital acute care and gastroenterology.
's marketed products include Acetadote
) Injection for the treatment of acetaminophen poisoning, Caldolor
) Injection, the first injectable treatment for pain and fever approved in
the United States
, and Kristalose
) for Oral Solution, a prescription laxative.
is dedicated to providing innovative products which improve quality of care for patients. For more information, please visit
Forward Looking Statements
This document may contain forward-looking statements, which are subject to certain risks and reflect
's current views on future events based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. As with any business, all phases of
's operations are subject to factors outside its control, and any one or combination of these factors could materially affect
's results of operations. These factors include market conditions, competition, an inability of manufacturers to produce
's products on a timely basis or a failure of manufacturers to comply with regulations applicable to pharmaceutical manufacturers, maintaining an effective sales and marketing infrastructure and other factors set forth under the headings "Risk factors" and "Management's discussion and analysis of financial condition and results of operations" in
's Form 10-K filed with the SEC on
March 11, 2011
. There can be no assurance that results anticipated by the Company will be realized or that they will have the expected effects. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The Company does not undertake any obligation to publicly revise these statements to reflect events after the date hereof.
SOURCE Cumberland Pharmaceuticals Inc.